An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

OBJECTIVE: In this phase II study, we aimed to investigate the efficacy and safety of single-dose [(131)I]meta-iodobenzylguanidine ((131)I-mIBG) therapy in patients with refractory pheochromocytoma and paraganglioma (PPGL). PATIENTS AND METHODS: This study was designed as an open-label, single-arm,...

Descripción completa

Detalles Bibliográficos
Autores principales: Inaki, Anri, Shiga, Tohru, Tsushima, Yoshito, Jinguji, Megumi, Wakabayashi, Hiroshi, Kayano, Daiki, Akatani, Norihito, Yamase, Takafumi, Kunita, Yuji, Watanabe, Satoru, Hiromasa, Tomo, Mori, Hiroshi, Hirata, Kenji, Watanabe, Shiro, Higuchi, Tetsuya, Tomonaga, Hiroyasu, Kinuya, Seigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897386/
https://www.ncbi.nlm.nih.gov/pubmed/34870794
http://dx.doi.org/10.1007/s12149-021-01699-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897386/
https://www.ncbi.nlm.nih.gov/pubmed/34870794
http://dx.doi.org/10.1007/s12149-021-01699-0

Ejemplares similares